ヒトパピローマウイルス（HPV）ワクチンの世界市場レポート 2025年

ヒトパピローマウイルス（HPV）ワクチン市場規模は、今後数年で急成長が見込まれます。2029年には複合年間成長率（CAGR）13.2％で108億9,000万米ドルに成長します。予測期間の成長は、健康の公平性とワクチンの公平性への取り組み、渡航時の健康勧告への盛り込み、標的を絞ったワクチン戦略、製薬業界の投資、遠隔医療、遠隔地でのワクチン接種などに起因しています。予測期間における主な動向としては、アジュバント技術の革新、LGBT+の健康におけるHPVワクチン接種の役割、免疫不全集団への注目、がん検診プログラムとの統合、地域ベースの教育プログラムなどが挙げられます。

ヒトパピローマウイルス（HPV）ワクチン市場は、HPV関連疾患の有病率の増加に牽引され、成長が見込まれています。これらのウイルス感染は皮膚や粘膜にイボとして現れることが多く、HPVワクチンはこれらの亜型を特異的に標的とするため、感染や関連疾患のリスクを効果的に軽減することができます。例えば、米国国立がん研究所の最近のデータによると、2023年には米国人女性で約13,960例の進行性子宮頸がんと診断され、4,310人が死亡すると予想されています。子宮頸がんなどのHPV関連疾患の憂慮すべき蔓延は、こうした健康リスクの抑制にHPVワクチンが不可欠な役割を果たすことを強調しています。

世界の予防接種率の増加は、ヒトパピローマウイルス（HPV）ワクチン市場の成長を促進します。予防接種率は、特定のワクチンまたは推奨される一連のワクチンを、定められた期間内に接種した人口の割合を示します。予防接種率の拡大は、HPVワクチンに対する需要の高まりを後押ししています。HPVワクチンは、定期的なワクチン接種プログラムに組み込まれているウイルス株に対する防御を提供し、1回の接種で複数の疾病の脅威に効果的に対処します。例えば、2023年7月現在、スイスに本部を置く国際的な公衆衛生機関である世界保健機関（WHO）のデータは、前向きな動向を明らかにしています。2022年には、予防接種を受けていないことを示すゼロ接種の子どもの数が、2021年の1,810万人から1,430万人に減少しました。さらに、女児におけるHPVワクチンの初回接種率は、2021年の16%から2022年には21%に上昇しました。これらの新興国開拓は、世界の予防接種率の上昇が当面のHPVワクチン市場の成長軌道にプラスの影響を与えることを強調しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界ヒトパピローマウイルス（HPV）ワクチンPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のヒトパピローマウイルス（HPV）ワクチン市場：成長率分析
• 世界のヒトパピローマウイルス（HPV）ワクチン市場の実績：規模と成長, 2019-2024
• 世界のヒトパピローマウイルス（HPV）ワクチン市場の予測：規模と成長, 2024-2029, 2034F
• 世界ヒトパピローマウイルス（HPV）ワクチン総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のヒトパピローマウイルス（HPV）ワクチン市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 四価
• 9価
• 二価
• 世界のヒトパピローマウイルス（HPV）ワクチン市場：疾患適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 子宮頸がん
• 肛門がん
• 外陰部および膣がん
• 陰茎がん
• 口腔咽頭がん
• その他の適応症
• 世界のヒトパピローマウイルス（HPV）ワクチン市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院および薬局
• 政府サプライヤー
• その他のチャンネル
• 世界のヒトパピローマウイルス（HPV）ワクチン市場：業界別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 官民連携
• 政府機関
• 医師
• その他の産業
• 世界のヒトパピローマウイルス（HPV）ワクチン市場、四価のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• HPV 4（サーバリックス）
• HPV 4（ガーダシル）
• 世界のヒトパピローマウイルス（HPV）ワクチン市場、タイプ別の九価のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• HPV 9（ガーダシル9）
• 世界のヒトパピローマウイルス（HPV）ワクチン市場、二価のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• HPV 2（サーバリックス）

第7章 地域別・国別分析

• 世界のヒトパピローマウイルス（HPV）ワクチン市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のヒトパピローマウイルス（HPV）ワクチン市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ヒトパピローマウイルス（HPV）ワクチン市場：競合情勢
• ヒトパピローマウイルス（HPV）ワクチン市場：企業プロファイル
  • Johnson & Johnson Co Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline Plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• AstraZeneca Pharma Ltd.
• Astellas Pharma Inc.
• CSL Limited
• UCB SA
• Serum Institute of India Pvt Ltd.
• Beijing Wantai Biological Pharmacy Enterprise Co Ltd.
• Emergent BioSolutions Inc.
• Bharat Biotech International Ltd.
• Walvax Biotechnology Co Ltd.
• Bavarian Nordic AS
• Biofarma Co
• Vaccitech Plc
• Inovio Pharmaceuticals Inc.
• R-Pharm LLC
• PathoVax LLC

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ヒトパピローマウイルス（HPV）ワクチン市場2029：新たな機会を提供する国
• ヒトパピローマウイルス（HPV）ワクチン市場2029：新たな機会を提供するセグメント
• ヒトパピローマウイルス（HPV）ワクチン市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

The Human Papillomavirus (HPV) Vaccine is a preventive vaccine designed to protect against specific strains of human papillomavirus, reducing the risk of infection. These vaccines play a crucial role in preventing most occurrences of cervical, vaginal, and vulvar cancers.

The primary types of Human Papillomavirus (HPV) vaccines are tetravalent, nonavalent, and bivalent. Tetravalent vaccines activate the body's defenses against four distinct antigens, providing an immunological response against four different viruses or microbes. These vaccines target disease indications such as cervical cancer, anal cancer, vulvar and vaginal cancer, penile cancer, oropharyngeal cancer, and others. Distribution channels include hospitals, retail pharmacies, government suppliers, and others. The industry verticals involved encompass public and private alliances, government entities, physicians, and others.

The human papillomavirus (HPV) vaccine market research report is one of a series of new reports from The Business Research Company that provides human papillomavirus (HPV) vaccine market statistics, including human papillomavirus (HPV) vaccine industry global market size, regional shares, competitors with a human papillomavirus (HPV) vaccine market share, detailed human papillomavirus (HPV) vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the human papillomavirus (HPV) vaccine industry. This human papillomavirus (HPV) vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The human papillomavirus (HPV) vaccine market size has grown rapidly in recent years. It will grow from $5.8 billion in 2024 to $6.63 billion in 2025 at a compound annual growth rate (CAGR) of 14.2%. The growth in the historic period can be attributed to initial vaccine development, medical guidelines and recommendations, government-sponsored vaccination campaigns, educational initiatives on HPV risks, improvement in vaccine accessibility

The human papillomavirus (HPV) vaccine market size is expected to see rapid growth in the next few years. It will grow to $10.89 billion in 2029 at a compound annual growth rate (CAGR) of 13.2%. The growth in the forecast period can be attributed to health equity and vaccine equity efforts, inclusion in travel health recommendations, targeted vaccination strategies, pharmaceutical industry investments, telemedicine and remote vaccination. Major trends in the forecast period include innovation in adjuvant technology, role of HPV vaccination in lgbtq+ health, focus on immunocompromised populations, integration with cancer screening programs, community-based education programs.

The human papillomavirus (HPV) vaccine market is poised for growth, driven by the increased prevalence of HPV-related diseases. These viral infections often manifest as warts on the skin or mucous membranes, and the HPV vaccine specifically targets these subtypes, effectively mitigating the risk of infection and associated diseases. For instance, recent data from the National Cancer Institute indicates an anticipated diagnosis of approximately 13,960 cases of aggressive cervical cancer in American women, with an expected 4,310 fatalities in 2023. The alarming prevalence of HPV-related diseases, such as cervical cancer, underscores the imperative role of the HPV vaccine in curbing these health risks.

Increasing global immunization coverage is poised to drive growth in the human papillomavirus (HPV) vaccine market. Immunization coverage denotes the percentage of a population that has received specific vaccines or a recommended set of vaccines within a defined timeframe. The expansion of immunization coverage fuels heightened demand for HPV vaccines, which provide protection against virus strains incorporated into routine vaccination programs, effectively addressing multiple disease threats with a single shot. For example, as of July 2023, data from the World Health Organization (WHO), an international public health organization based in Switzerland, revealed positive trends. In 2022, the number of zero-dose children, indicating those who did not receive any vaccinations, decreased from 18.1 million in 2021 to 14.3 million. Additionally, global coverage for the initial dose of the HPV vaccine in girls witnessed an increase from 16% in 2021 to 21% in 2022. These developments underscore the positive impact of rising global immunization coverage on the growth trajectory of the HPV vaccine market in the foreseeable future.

A key trend in the human papillomavirus (HPV) vaccine market is the focus on product innovation, with companies adopting new technologies to maintain their market standing. For Instance, In January 2023, the Serum Institute of India introduced CERVAVAC, the first quadrivalent HPV vaccine developed entirely by Indian scientists. This innovative vaccine, aimed at immunizing girls aged 9 to 14 against cervical cancer, signifies a noteworthy advancement in the field and addresses the need for affordable and cost-effective solutions.

Major companies in the human papillomavirus (HPV) vaccine market are prioritizing innovative approaches, such as awareness campaigns aimed at educating communities about the benefits of vaccination. These campaigns are strategic initiatives designed to inform a specific audience or the general public about a particular issue, cause, product, or service. For example, in January 2023, the Family Planning Association of India, a charity based in India, launched a vaccine drive against cervical cancer, targeting girls aged 9 to 14 years. This nationwide HPV vaccination initiative seeks to protect girls and women from cervical cancer using a quadrivalent vaccine that targets key strains of the virus. The goal is to vaccinate approximately 50 million girls while raising awareness and improving access in both urban and rural areas.

In January 2022, Biocon Biologics Ltd., an India-based biopharmaceutical company, merged with the Serum Institute of India. This collaboration not only ensures a committed revenue stream and associated margins for Biocon Biologics Ltd. but also facilitates the development of antibodies targeting infectious diseases, including HPV. The Serum Institute of India, known for manufacturing qHPV vaccines and immuno-biologicals, reinforces the collective efforts to combat HPV-related health challenges.

Major companies operating in the human papillomavirus (HPV) vaccine market include Johnson & Johnson Co, Merck & Co Inc., Novartis AG, Sanofi SA, GlaxoSmithKline Plc, AstraZeneca Pharma Ltd., Astellas Pharma Inc., CSL Limited, UCB SA, Serum Institute of India Pvt Ltd., Beijing Wantai Biological Pharmacy Enterprise Co Ltd., Emergent BioSolutions Inc., Bharat Biotech International Ltd., Walvax Biotechnology Co Ltd., Bavarian Nordic AS, Biofarma Co, Vaccitech Plc, Inovio Pharmaceuticals Inc., R-Pharm LLC, PathoVax LLC

North America was the largest region in the human papillomavirus (HPV) vaccine market in 2024. The regions covered in the human papillomavirus (hpv) vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the human papillomavirus (hpv) vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The human papillomavirus (HPV) vaccine market consists of sales of gardasil 9, gardasil, and cervarix. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Human Papillomavirus (HPV) Vaccine Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on human papillomavirus (hpv) vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for human papillomavirus (hpv) vaccine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The human papillomavirus (hpv) vaccine market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Tetravalent; Nonavalent; Bivalent
• 2) By Disease Indication: Cervical Cancer; Anal Cancer; Vulvar And Vaginal Cancer; Penile Cancer; Oropharyngeal Cancer; Other Indications
• 3) By Distribution Channel: Hospital And Retail Pharmacies; Government Suppliers; Other Channels
• 4) By Industry Vertical: Public And Private Alliance; Government Entities; Physicians; Other Industries
• Subsegments:
• 1) By Tetravalent: HPV 4 (Cervarix); HPV 4 (Gardasil)
• 2) By Nonavalent: HPV 9 (Gardasil 9)
• 3) By Bivalent: HPV 2 (Cervarix)
• Companies Mentioned: Johnson & Johnson Co; Merck & Co Inc.; Novartis AG; Sanofi SA; GlaxoSmithKline Plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Human Papillomavirus (HPV) Vaccine Market Characteristics

3. Human Papillomavirus (HPV) Vaccine Market Trends And Strategies

4. Human Papillomavirus (HPV) Vaccine Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Human Papillomavirus (HPV) Vaccine Growth Analysis And Strategic Analysis Framework

• 5.1. Global Human Papillomavirus (HPV) Vaccine PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Human Papillomavirus (HPV) Vaccine Market Growth Rate Analysis
• 5.4. Global Human Papillomavirus (HPV) Vaccine Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Human Papillomavirus (HPV) Vaccine Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Human Papillomavirus (HPV) Vaccine Total Addressable Market (TAM)

6. Human Papillomavirus (HPV) Vaccine Market Segmentation

• 6.1. Global Human Papillomavirus (HPV) Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tetravalent
• Nonavalent
• Bivalent
• 6.2. Global Human Papillomavirus (HPV) Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cervical Cancer
• Anal Cancer
• Vulvar And Vaginal Cancer
• Penile Cancer
• Oropharyngeal Cancer
• Other Indications
• 6.3. Global Human Papillomavirus (HPV) Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital And Retail Pharmacies
• Government Suppliers
• Other Channels
• 6.4. Global Human Papillomavirus (HPV) Vaccine Market, Segmentation By Industry Vertical, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Public And Private Alliance
• Government Entities
• Physicians
• Other Industries
• 6.5. Global Human Papillomavirus (HPV) Vaccine Market, Sub-Segmentation Of Tetravalent, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• HPV 4 (Cervarix)
• HPV 4 (Gardasil)
• 6.6. Global Human Papillomavirus (HPV) Vaccine Market, Sub-Segmentation Of Nonavalent, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• HPV 9 (Gardasil 9)
• 6.7. Global Human Papillomavirus (HPV) Vaccine Market, Sub-Segmentation Of Bivalent, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• HPV 2 (Cervarix)

7. Human Papillomavirus (HPV) Vaccine Market Regional And Country Analysis

• 7.1. Global Human Papillomavirus (HPV) Vaccine Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Human Papillomavirus (HPV) Vaccine Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Human Papillomavirus (HPV) Vaccine Market

• 8.1. Asia-Pacific Human Papillomavirus (HPV) Vaccine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Human Papillomavirus (HPV) Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Human Papillomavirus (HPV) Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Human Papillomavirus (HPV) Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Human Papillomavirus (HPV) Vaccine Market

• 9.1. China Human Papillomavirus (HPV) Vaccine Market Overview
• 9.2. China Human Papillomavirus (HPV) Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Human Papillomavirus (HPV) Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Human Papillomavirus (HPV) Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Human Papillomavirus (HPV) Vaccine Market

• 10.1. India Human Papillomavirus (HPV) Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Human Papillomavirus (HPV) Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Human Papillomavirus (HPV) Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Human Papillomavirus (HPV) Vaccine Market

• 11.1. Japan Human Papillomavirus (HPV) Vaccine Market Overview
• 11.2. Japan Human Papillomavirus (HPV) Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Human Papillomavirus (HPV) Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Human Papillomavirus (HPV) Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Human Papillomavirus (HPV) Vaccine Market

• 12.1. Australia Human Papillomavirus (HPV) Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Human Papillomavirus (HPV) Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Human Papillomavirus (HPV) Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Human Papillomavirus (HPV) Vaccine Market

• 13.1. Indonesia Human Papillomavirus (HPV) Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Human Papillomavirus (HPV) Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Human Papillomavirus (HPV) Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Human Papillomavirus (HPV) Vaccine Market

• 14.1. South Korea Human Papillomavirus (HPV) Vaccine Market Overview
• 14.2. South Korea Human Papillomavirus (HPV) Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Human Papillomavirus (HPV) Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Human Papillomavirus (HPV) Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Human Papillomavirus (HPV) Vaccine Market

• 15.1. Western Europe Human Papillomavirus (HPV) Vaccine Market Overview
• 15.2. Western Europe Human Papillomavirus (HPV) Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Human Papillomavirus (HPV) Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Human Papillomavirus (HPV) Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Human Papillomavirus (HPV) Vaccine Market

• 16.1. UK Human Papillomavirus (HPV) Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Human Papillomavirus (HPV) Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Human Papillomavirus (HPV) Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Human Papillomavirus (HPV) Vaccine Market

• 17.1. Germany Human Papillomavirus (HPV) Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Human Papillomavirus (HPV) Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Human Papillomavirus (HPV) Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Human Papillomavirus (HPV) Vaccine Market

• 18.1. France Human Papillomavirus (HPV) Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Human Papillomavirus (HPV) Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Human Papillomavirus (HPV) Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Human Papillomavirus (HPV) Vaccine Market

• 19.1. Italy Human Papillomavirus (HPV) Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Human Papillomavirus (HPV) Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Human Papillomavirus (HPV) Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Human Papillomavirus (HPV) Vaccine Market

• 20.1. Spain Human Papillomavirus (HPV) Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Human Papillomavirus (HPV) Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Human Papillomavirus (HPV) Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Human Papillomavirus (HPV) Vaccine Market

• 21.1. Eastern Europe Human Papillomavirus (HPV) Vaccine Market Overview
• 21.2. Eastern Europe Human Papillomavirus (HPV) Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Human Papillomavirus (HPV) Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Human Papillomavirus (HPV) Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Human Papillomavirus (HPV) Vaccine Market

• 22.1. Russia Human Papillomavirus (HPV) Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Human Papillomavirus (HPV) Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Human Papillomavirus (HPV) Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Human Papillomavirus (HPV) Vaccine Market

• 23.1. North America Human Papillomavirus (HPV) Vaccine Market Overview
• 23.2. North America Human Papillomavirus (HPV) Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Human Papillomavirus (HPV) Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Human Papillomavirus (HPV) Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Human Papillomavirus (HPV) Vaccine Market

• 24.1. USA Human Papillomavirus (HPV) Vaccine Market Overview
• 24.2. USA Human Papillomavirus (HPV) Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Human Papillomavirus (HPV) Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Human Papillomavirus (HPV) Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Human Papillomavirus (HPV) Vaccine Market

• 25.1. Canada Human Papillomavirus (HPV) Vaccine Market Overview
• 25.2. Canada Human Papillomavirus (HPV) Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Human Papillomavirus (HPV) Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Human Papillomavirus (HPV) Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Human Papillomavirus (HPV) Vaccine Market

• 26.1. South America Human Papillomavirus (HPV) Vaccine Market Overview
• 26.2. South America Human Papillomavirus (HPV) Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Human Papillomavirus (HPV) Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Human Papillomavirus (HPV) Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Human Papillomavirus (HPV) Vaccine Market

• 27.1. Brazil Human Papillomavirus (HPV) Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Human Papillomavirus (HPV) Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Human Papillomavirus (HPV) Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Human Papillomavirus (HPV) Vaccine Market

• 28.1. Middle East Human Papillomavirus (HPV) Vaccine Market Overview
• 28.2. Middle East Human Papillomavirus (HPV) Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Human Papillomavirus (HPV) Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Human Papillomavirus (HPV) Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Human Papillomavirus (HPV) Vaccine Market

• 29.1. Africa Human Papillomavirus (HPV) Vaccine Market Overview
• 29.2. Africa Human Papillomavirus (HPV) Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Human Papillomavirus (HPV) Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Human Papillomavirus (HPV) Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Human Papillomavirus (HPV) Vaccine Market Competitive Landscape And Company Profiles

• 30.1. Human Papillomavirus (HPV) Vaccine Market Competitive Landscape
• 30.2. Human Papillomavirus (HPV) Vaccine Market Company Profiles
  • 30.2.1. Johnson & Johnson Co Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. GlaxoSmithKline Plc Overview, Products and Services, Strategy and Financial Analysis

31. Human Papillomavirus (HPV) Vaccine Market Other Major And Innovative Companies

• 31.1. AstraZeneca Pharma Ltd.
• 31.2. Astellas Pharma Inc.
• 31.3. CSL Limited
• 31.4. UCB SA
• 31.5. Serum Institute of India Pvt Ltd.
• 31.6. Beijing Wantai Biological Pharmacy Enterprise Co Ltd.
• 31.7. Emergent BioSolutions Inc.
• 31.8. Bharat Biotech International Ltd.
• 31.9. Walvax Biotechnology Co Ltd.
• 31.10. Bavarian Nordic AS
• 31.11. Biofarma Co
• 31.12. Vaccitech Plc
• 31.13. Inovio Pharmaceuticals Inc.
• 31.14. R-Pharm LLC
• 31.15. PathoVax LLC

32. Global Human Papillomavirus (HPV) Vaccine Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Human Papillomavirus (HPV) Vaccine Market

34. Recent Developments In The Human Papillomavirus (HPV) Vaccine Market

35. Human Papillomavirus (HPV) Vaccine Market High Potential Countries, Segments and Strategies

• 35.1 Human Papillomavirus (HPV) Vaccine Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Human Papillomavirus (HPV) Vaccine Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Human Papillomavirus (HPV) Vaccine Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer